Indian plans to develop biotechnology sector

29 March 2016
2019_biotech_test_vial_discovery_big

A joint action plan has been set into motion in India to help the biotech sector reach $100 billion by 2025. Even as the government is going all out showcasing India’s biotech strength and capacity to attract investors, all efforts are being made to strengthen the bio-cluster ecosystem across the country, reports The Pharma Letter’s India correspondent.

Apart from setting up incubation centers in the state of Karnataka at Dharwad, Belagavi, Bidar and Mangaluru, the government is also keen to promote the creation of the Bengaluru-Boston biotech corridor. The idea came about after a letter of intent was signed to create the US-Indo Life Science Sister Innovation Hub, by the Center for Cellular and Molecular Platform in Bengaluru, and The California Institute for Quantitative Biosciences.

India's Department of biotechnology (DBT) has called for investments in creating a pool of quality talent. Professor K VijayRaghavan, Secretary, Department of Biotechnology, said biotechnology in India has crossed significant milestones: "With the experience of 30 years, DBT’s endeavor will be to further improve our processes and culture so that we expand our reach and depth effectively," he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology